DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in ...
Dear Dr. Gott: I am a healthy 52-year-old female who has suffered from DSAP (disseminated superficial actinic porokeratosis) most of my adult life. I have hundreds of bright red spots on each arm and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results